Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Angiotensin-converting enzyme gene polymorphism and digestive system cancer risk: A meta-analysis based on 9656 subjects.

Abdeahad H, Avan A, Khazaei M, Soleimanpour S, Ferns GA, Fiuji H, Ryzhikov M, Bahrami A, Hassanian SM.

J Cell Biochem. 2019 Sep 2. doi: 10.1002/jcb.28955. [Epub ahead of print]

PMID:
31478246
2.

Prognostic value of high mobility group protein A2 (HMGA2) over-expression in cancer progression.

Binabaj MM, Soleimani A, Rahmani F, Avan A, Khazaei M, Fiuji H, Soleimanpour S, Ryzhikov M, Ferns GA, Bahrami A, Hassanian SM.

Gene. 2019 Jul 20;706:131-139. doi: 10.1016/j.gene.2019.04.088. Epub 2019 May 2.

PMID:
31055021
3.

Mycobacterium tuberculosis Ag85b:hfcγ1 recombinant fusion protein as a selective receptor-dependent delivery system for antigen presentation.

Karbalaei Zadeh Babaki M, Taghiabadi M, Soleimanpour S, Saleh Moghadam M, Mosavat A, Amini AA, Mohammadi A, Rezaee SA.

Microb Pathog. 2019 Apr;129:68-73. doi: 10.1016/j.micpath.2019.01.045. Epub 2019 Jan 31.

PMID:
30711546
4.

Therapeutic potency of crocin in the treatment of inflammatory diseases: Current status and perspective.

Pashirzad M, Shafiee M, Avan A, Ryzhikov M, Fiuji H, Bahreyni A, Khazaei M, Soleimanpour S, Hassanian SM.

J Cell Physiol. 2019 Jan 23. doi: 10.1002/jcp.28177. [Epub ahead of print] Review.

PMID:
30673132
5.

Direct drug susceptibility testing of Mycobacterium tuberculosis using the proportional method: A multicenter study.

Amini S, Hoffner S, Allahyar Torkaman MR, Hamzehloo G, Nasiri MJ, Salehi M, Sami Kashkooli G, Shahraki MS, Mohsenpoor M, Soleimanpour S, Mir R.

J Glob Antimicrob Resist. 2019 Jun;17:242-244. doi: 10.1016/j.jgar.2018.12.022. Epub 2019 Jan 7.

PMID:
30630107
6.

The prognostic potential of long noncoding RNA HOTAIR expression in human digestive system carcinomas: A meta-analysis.

Abdeahad H, Avan A, Pashirzad M, Khazaei M, Soleimanpour S, Ferns GA, Fiuji H, Ryzhikov M, Bahrami A, Hassanian SM.

J Cell Physiol. 2019 Jul;234(7):10926-10933. doi: 10.1002/jcp.27918. Epub 2018 Dec 19.

PMID:
30569489
7.

Therapeutic potency of Wnt signaling antagonists in the pathogenesis of prostate cancer, current status and perspectives.

Pashirzad M, Shafiee M, Khazaei M, Fiuji H, Ryzhikov M, Soleimanpour S, Hesari A, Avan A, Hassanian SM.

J Cell Physiol. 2019 Feb;234(2):1237-1247. doi: 10.1002/jcp.27137. Epub 2018 Sep 7. Review.

PMID:
30191954
8.

Therapeutic potential of A2 adenosine receptor pharmacological regulators in the treatment of cardiovascular diseases, recent progress, and prospective.

Bahreyni A, Avan A, Shabani M, Ryzhikov M, Fiuji H, Soleimanpour S, Khazaei M, Hassanian SM.

J Cell Physiol. 2019 Feb;234(2):1295-1299. doi: 10.1002/jcp.27161. Epub 2018 Aug 26. Review.

PMID:
30146778
9.

The prognostic value of long noncoding RNA MEG3 expression in the survival of patients with cancer: A meta-analysis.

Binabaj MM, Bahrami A, Bahreyni A, Shafiee M, Rahmani F, Khazaei M, Soleimanpour S, Ghorbani E, Fiuji H, Ferns GA, Ryzhikov M, Avan A, Hassanian SM.

J Cell Biochem. 2018 Nov;119(11):9583-9590. doi: 10.1002/jcb.27276. Epub 2018 Aug 20.

PMID:
30129051
10.

Are chitosan natural polymers suitable as adjuvant/delivery system for anti-tuberculosis vaccines?

Khademi F, Taheri RA, Yousefi Avarvand A, Vaez H, Momtazi-Borojeni AA, Soleimanpour S.

Microb Pathog. 2018 Aug;121:218-223. doi: 10.1016/j.micpath.2018.05.035. Epub 2018 May 23. Review.

PMID:
29800697
11.

Relation between lower respiratory tract microbiota and type of immune response against tuberculosis.

Nakhaee M, Rezaee A, Basiri R, Soleimanpour S, Ghazvini K.

Microb Pathog. 2018 Jul;120:161-165. doi: 10.1016/j.micpath.2018.04.054. Epub 2018 May 1.

PMID:
29727705
12.

Therapeutic potency of mTOR signaling pharmacological inhibitors in the treatment of proinflammatory diseases, current status, and perspectives.

Soltani A, Bahreyni A, Boroumand N, Roshan MK, Khazaei M, Ryzhikov M, Soleimanpour S, Avan A, Hassanian SM.

J Cell Physiol. 2018 Jun;233(6):4783-4790. doi: 10.1002/jcp.26276. Epub 2017 Dec 26. Review.

PMID:
29165795
13.

Toll like receptor signaling pathway as a potential therapeutic target in colorectal cancer.

Moradi-Marjaneh R, Hassanian SM, Fiuji H, Soleimanpour S, Ferns GA, Avan A, Khazaei M.

J Cell Physiol. 2018 Aug;233(8):5613-5622. doi: 10.1002/jcp.26273. Epub 2018 Mar 1. Review.

PMID:
29150944
14.

The current status and perspectives regarding the clinical implication of intracellular calcium in breast cancer.

Tajbakhsh A, Pasdar A, Rezaee M, Fazeli M, Soleimanpour S, Hassanian SM, FarshchiyanYazdi Z, Younesi Rad T, Ferns GA, Avan A.

J Cell Physiol. 2018 Aug;233(8):5623-5641. doi: 10.1002/jcp.26277. Epub 2018 Feb 28. Review.

PMID:
29150934
15.

Multi-stage subunit vaccines against Mycobacterium tuberculosis: an alternative to the BCG vaccine or a BCG-prime boost?

Khademi F, Derakhshan M, Yousefi-Avarvand A, Tafaghodi M, Soleimanpour S.

Expert Rev Vaccines. 2018 Jan;17(1):31-44. doi: 10.1080/14760584.2018.1406309. Epub 2017 Nov 22. Review.

PMID:
29148853
16.

Antigen 85 complex as a powerful Mycobacterium tuberculosis immunogene: Biology, immune-pathogenicity, applications in diagnosis, and vaccine design.

Karbalaei Zadeh Babaki M, Soleimanpour S, Rezaee SA.

Microb Pathog. 2017 Nov;112:20-29. doi: 10.1016/j.micpath.2017.08.040. Epub 2017 Sep 20. Review.

PMID:
28942172
17.

In vitro bactericidal activities of two novel dihydropyridine derivatives against Mycobacterium tuberculosis.

Zandhaghighi M, Hadizadeh F, Soleimanpour S, Meshkat Z, Rezaee SA, Derakhshan M, Ghazvini K.

J Infect Dev Ctries. 2017 Jun 27;11(6):453-458. doi: 10.3855/jidc.7966.

18.

Urinary infection due to Balantioides coli: a rare accidental zoonotic disease in an addicted and diabetic young female in Iran.

Soleimanpour S, Babaei A, Roudi AM, Raeisalsadati SS.

JMM Case Rep. 2016 Feb 5;3(1):e000102. doi: 10.1099/jmmcr.0.000102. eCollection 2016 Feb.

19.

CFP10: mFcγ2 as a novel tuberculosis vaccine candidate increases immune response in mouse.

Baghani AA, Soleimanpour S, Farsiani H, Mosavat A, Yousefi M, Meshkat Z, Rezaee SA, Jamehdar SA, Eydgahi MR, Sadeghian H, Ghazvini K.

Iran J Basic Med Sci. 2017 Feb;20(2):122-130. doi: 10.22038/ijbms.2017.8231.

20.

Molecular identification of Mycobacterium tuberculosis complex isolated by Region of Differentiation (RD) typing from tuberculosis patients in Khorasan Razavi.

Jalalimehr M, Mosavari N, Soleimanpour S.

Int J Mycobacteriol. 2016 Dec;5 Suppl 1:S189. doi: 10.1016/j.ijmyco.2016.10.026. Epub 2016 Oct 27.

21.

Elevated prevalence of multidrug-resistant Acinetobacter baumannii with extensive genetic diversity in the largest burn centre of northeast Iran.

Sarhaddi N, Soleimanpour S, Farsiani H, Mosavat A, Dolatabadi S, Salimizand H, Amel Jamehdar S.

J Glob Antimicrob Resist. 2017 Mar;8:60-66. doi: 10.1016/j.jgar.2016.10.009. Epub 2016 Dec 21.

PMID:
28011349
22.

Construction and immunogenicity of a new Fc-based subunit vaccine candidate against Mycobacterium tuberculosis.

Kebriaei A, Derakhshan M, Meshkat Z, Eidgahi MR, Rezaee SA, Farsiani H, Mosavat A, Soleimanpour S, Ghazvini K.

Mol Biol Rep. 2016 Sep;43(9):911-22. doi: 10.1007/s11033-016-4024-9. Epub 2016 Jun 1.

PMID:
27251218
23.

Fc-based delivery system enhances immunogenicity of a tuberculosis subunit vaccine candidate consisting of the ESAT-6:CFP-10 complex.

Farsiani H, Mosavat A, Soleimanpour S, Sadeghian H, Akbari Eydgahi MR, Ghazvini K, Sankian M, Aryan E, Jamehdar SA, Rezaee SA.

Mol Biosyst. 2016 Jun 21;12(7):2189-201. doi: 10.1039/c6mb00174b.

PMID:
27138226
24.

Fcγ1 fragment of IgG1 as a powerful affinity tag in recombinant Fc-fusion proteins: immunological, biochemical and therapeutic properties.

Soleimanpour S, Hassannia T, Motiee M, Amini AA, Rezaee SA.

Crit Rev Biotechnol. 2017 May;37(3):371-392. doi: 10.3109/07388551.2016.1163323. Epub 2016 Apr 6. Review.

PMID:
27049690
25.

Fused Mycobacterium tuberculosis multi-stage immunogens with an Fc-delivery system as a promising approach for the development of a tuberculosis vaccine.

Mosavat A, Soleimanpour S, Farsiani H, Sadeghian H, Ghazvini K, Sankian M, Jamehdar SA, Rezaee SA.

Infect Genet Evol. 2016 Apr;39:163-172. doi: 10.1016/j.meegid.2016.01.027. Epub 2016 Feb 4.

PMID:
26835592
26.

Construction of Mycobacterium tuberculosis ESAT-6 fused to human Fcγ of IgG1: To target FcγR as a delivery system for enhancement of immunogenicity.

Soleimanpour S, Mohammadi A, Ghazvini K, Jamehdar SA, Sadeghian H, Taghiabadi M, Rezaee SAR.

Gene. 2016 Apr 15;580(2):111-117. doi: 10.1016/j.gene.2016.01.009. Epub 2016 Jan 8.

PMID:
26778208
27.

APC targeting enhances immunogenicity of a novel multistage Fc-fusion tuberculosis vaccine in mice.

Soleimanpour S, Farsiani H, Mosavat A, Ghazvini K, Eydgahi MR, Sankian M, Sadeghian H, Meshkat Z, Rezaee SA.

Appl Microbiol Biotechnol. 2015 Dec;99(24):10467-80. doi: 10.1007/s00253-015-6952-z. Epub 2015 Sep 15.

PMID:
26373723
28.
29.

Sequence Analysis of lip R: A Good Method for Molecular Epidemiology of Clinical Isolates of Mycobacterium tuberculosis.

Saedi S, Youssefi M, Safdari H, Soleimanpour S, Marouzi P, Ghazvini K.

Curr Microbiol. 2015 Oct;71(4):443-8. doi: 10.1007/s00284-015-0856-0. Epub 2015 Jun 11.

PMID:
26063445
30.

Limited genetic diversity and extensive antimicrobial resistance in clinical isolates of Acinetobacter baumannii in north-east Iran.

Farsiani H, Mosavat A, Soleimanpour S, Nasab MN, Salimizand H, Jamehdar SA, Ghazvini K, Aryan E, Baghani AA.

J Med Microbiol. 2015 Jul;64(7):767-73. doi: 10.1099/jmm.0.000090. Epub 2015 May 19.

PMID:
25991693
31.

Extensive Genetic Diversity among Clinical Isolates of Mycobacterium tuberculosis in Central Province of Iran.

Soleimanpour S, Hamedi Asl D, Tadayon K, Farazi AA, Keshavarz R, Soleymani K, Seddighinia FS, Mosavari N.

Tuberc Res Treat. 2014;2014:195287. doi: 10.1155/2014/195287. Epub 2014 Nov 19.

32.

Antibacterial activity of Glycyrrhiza glabra against oral pathogens: an in vitro study.

Sedighinia F, Safipour Afshar A, Soleimanpour S, Zarif R, Asili J, Ghazvini K.

Avicenna J Phytomed. 2012 Summer;2(3):118-24.

Supplemental Content

Loading ...
Support Center